Skip to main content
Clinical Trials/NL-OMON47401
NL-OMON47401
Recruiting
Not Applicable

Validation of Pharmacokinetic and Pharmacodynamic Assays for determination of Nivolumab and Pembrolizumab concentrations, and the occupancy of their target receptor Programmed Death-1 (PD-1) on T-cells - Developing Assays for Anti-PD-1 monoclonal antibodies

Antoni van Leeuwenhoek Ziekenhuis0 sites70 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
metastasized cancer
Sponsor
Antoni van Leeuwenhoek Ziekenhuis
Enrollment
70
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Sponsor
Antoni van Leeuwenhoek Ziekenhuis

Eligibility Criteria

Inclusion Criteria

  • Patients with solid tumors who will start treatment with nivolumab or pembrolizumab and are willing to undergo blood sampling and/or donate residual material.

Exclusion Criteria

  • Patients with known alcoholism, drug addiction, psychotic disorders in the history and/or other reasons, for which they are not amendable for adequate follow up.
  • Uncontrolled infectious disease or known HIV\-1 or HIV\-2 type patients.

Outcomes

Primary Outcomes

Not specified

Similar Trials